direkt zum Inhalt springen

direkt zum Hauptnavigationsmenü

Sie sind hier

TU Berlin

Page Content

Pharmaceuticals

2016

  • Panteli D, Nolting A, Eckhart H, Kulig M, Busse R (2016): Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward [1]

2015

  • Busse R, Panteli D, Henschke C (2015): Arzneimittelversorgung in der GKV und 15 anderen europäischen Gesundheitssystemen. Universitätsverlag der TU Berlin [2]
  • Henschel F, Redaelli M, Siegel M, Stock S (2015): Correlation of Incident Potentially Inappropriate Medication Prescriptions and Hospitalisation: An Analysis Based on the PRISCUS List [3]
  • Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M (2015): From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Research Policy and Systems [4]

2014

  • Habicht T, Van Ginneken E. Alleviating high out –of-pocket spending on drugs: practical examples from Estonia. Eurohealth 2014; 20(2): 29-32. (ISSN 1356-1030) [5]
  • San Miguel L, Augustin U, Busse R, Knai C, Rubert G, Sihvo S, .. (2014): Recognition of pharmaceutical prescriptions across the European Union: A comparison of five Member States’ policies and practices. Health Policy 116(2-3): 206-213 [6]
  • Stock S, Redaelli M, Simic D, Siegel M, Henschel F (2014): Risk factors for the prescription of potentially inappropriate medication (PIM) in the elderly. Wien klin Wochenschr 126:604-612 (DOI: 10.1007/s00508-014-0589-2). [7]

2013

  • Henschke C, Sundmacher L, Busse R (2013): Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation. Health Policy 109(3): 209-225 (DOI 10.1016/j.healthpol.2012.12.005) [8]
  • Rohova M, Dimova A, Mutafova E, Atanasova E, Koeva S, Van Ginneken E (2013): Balancing regulation and free markets: The Bulgarian pharmaceutical sector. Eurohealth 2013; 19(1): 33-36. [9]
  • San Miguel L, Baeten R, Remme R, Busse R, Gil J, Knai C, Mäkinen M, Rubert G, Mckee M (2013): Obstacles to the recognition of medical prescriptions issued in one EU country and presented in another. Eur J Public Health 23(6) (DOI 10.1093/eurpub/ckt071) [10]

2012

  • Kreis J, Busse R (2012): From evidence assessments to coverage decisions? The case example of glinides in Germany. Health Policy 104(1): 27-31 [11]

2011

  • Mangiapane S, Busse R (2011): Prescription Prevalence and Continuing Medication Use for Secondary Prevention After Myocardial Infarction: the Reality of Care Revealed by Claims Data Analysis. Dtsch Arztebl Int 2011; 108(50): 856-62 [12]
  • Ognyanova D, Zentner A, Busse R (2011): Pharmaceutical reform 2010 in Germany: striking a balance between innovation and affordability. Eurohealth 17(1): 11-13 [13]
  • Zentner A, Busse R (2011): Bewertung von Arzneimitteln – wie gehen andere Länder vor? G+G Wissenschaft 11(1): 25-34 [14]

2007

  • Behrend C, Felder S, Busse R (2007): Susceptibility to Strategy of the Drug Component of the IPHCC+RxGroups Classification System in a Risk-Adjusted Morbidity Compensation Scheme - A Conceptional and Data-Supported Analysis. Gesundheitswesen 69(1): 1-10 [15]
  • Mangiapane S, Blettner M, Schlattmann P (2007): Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoedidemiology and Drug Safety [16]

2006

  • Lange-Lindberg A-M, Velasco Garrido, Busse R (2006): Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Tech [17]

2005

  • Busse R, Schreyögg J, Henke K-D (2005): Pharmaceutical Regulation in Germany: improving efficiency and controlling expenditures. International Journal of Health Planning and Management 20(4): 329-349 [18]
  • Gericke CA, Riesberg A, Busse R (2005): Ethical issues in funding orphan drug research and development. J Med Ethics (31) S. 164-168 [19]
  • Schreyögg J, Busse R (2005): Physician drug budgets in Germany: effects on prescription behaviour. Journal of Pharmaceutical Finance, Economics & Policy 14(3): 77-95 [20]
  • Zentner A, Velasco Garrido M, Busse R (2005): Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Köln: DIMDI [21]

2003

  • Böger GI, Hoopmann M, Busse R, Budinger M, Welte T, Böger R (2003): Arzneimittelverordnungen bei koronarer Herzkrankheit: Werden die Therapie­empfehlungen beachtet? Zeitschrift für Kardiologie 92(6): 466-475 [22]
  • Dixon A, Riesberg A, Weinbrenner S, Saka O, Le Grand J, Busse R (2003). Complementary and alternative medicine in the UK and Germany: A synthesis of research and evidence on supply and demand. London, Berlin: Anglo-German Foundation [23]
  • Krauth C, Jalivand N, Welte T, Busse R (2003): Cystic Fibrosis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmaco­economics 21(14): 1001-1024 [24]
  • Velasco-Garrido M, Busse R (2003): Whose "wish bias"? Ann Oncol 2003;14:1154 [25]

2001

  • Perleth M, Busse R (2001): Health Technology Assessment of oral anticoagulation following heart valve replacement. Eur Heart J Suppl 3: Q60-64 [26]

2000

  • Köhler G, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH (2000): Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. International Journal of Clinical Pharmacology and Therapeutics 38(1 [27]

To top

------ Links: ------

Zusatzinformationen / Extras

Quick Access:

Schnellnavigation zur Seite über Nummerneingabe

Copyright TU Berlin 2008